2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Plasma Cell Disorders, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

4741 Broader modulation of B-cell biology by tafasitamab compared with rituximab: Implications for autoimmune disease

Daniel Merenich, Jun Guan2, Athena Le3, Yue Zhang4, Liang-Chuan Steve Wang5, Chryssa Kanellopoulou6
1 Incyte Corporation, Wilmington, Delaware, United States
2 Incyte Corporation, Wilmington, Delaware, United States
3 Incyte Corporation, Wilmington, Delaware, United States
4 Incyte Corporation, Wilmington, Delaware, United States
5 Incyte Corporation, Wilmington, Delaware, United States
6 Incyte Corporation, Wilmington, Delaware, United States

Introduction: Tafasitamab is a humanized monoclonal antibody targeting CD19, a transmembrane protein central to B-cell receptor signaling and survival; it is Fc-engineered to enhance FcγR-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell phagocytosis (ADCP), while also inducing direct cytotoxicity. The safety and efficacy of tafasitamab is being evaluated in a phase 2 study of adults with primary autoimmune blood cell disorders (NCT07104565). Pathogenic B cells and autoantibody production are central drivers of autoimmune blood diseases, thus effective B-cell depletion is a key therapeutic strategy. Tafasitamab has been shown to effectively target and deplete CD19+ B-cell lymphoma cells when combined with lenalidomide and rituximab in preclinical studies (Pirosa et al., Hum Vaccin Immunother 2024; Lazic et al., Leuk Lymphoma 2025) and has demonstrated efficacy in combination therapy clinical trials in patients with follicular lymphoma (inMIND: Sehn et al., Lancet 2026) and diffuse large B-cell lymphoma (L-MIND: Salles et al., Lancet 2020; frontMIND: Lenz et al., Lancet 2026). Targeting CD20 with rituximab has demonstrated clinical benefit; however, targeting CD19 covers a broader spectrum of B-lineage cells. Here, we compare the mechanisms of action of tafasitamab and rituximab and evaluate whether targeting CD19 enables broader B-cell depletion over CD20.

Methods: Tafasitamab and rituximab were compared across mechanistic assays evaluating ADCC, ADCP, complement-dependent cytotoxicity (CDC), direct apoptosis of B cells, and B-cell proliferation. B‑cell and plasmablast/plasma cell depletion with tafasitamab or rituximab were assessed in vitro in: (1) primary human tonsil cells with natural killer cells; (2) peripheral blood mononuclear cells (PBMCs); (3) healthy bone marrow cells; and (4) PBMCs from patients with warm autoimmune hemolytic anemia (wAIHA). B cells were phenotyped and depletion was measured using flow cytometry. In vivo B-cell depletion was evaluated in hCD34-engrafted NSG SGM3-IL-15 mice after treatment with tafasitamab or rituximab.

Results: Tafasitamab and rituximab demonstrated shared and distinct functional profiles for B-cell targeting and depletion. Both agents showed strong activation of immune effector functions. Tafasitamab and rituximab each mediated robust ADCC and ADCP, and both antibodies induced direct apoptosis of target B cells. Rituximab displayed potent CDC activity, whereas tafasitamab did not. Distinct differences were also observed in modulation of B‑cell biology beyond cytotoxicity. Tafasitamab inhibited B‑cell proliferation, whereas rituximab had no measurable effects (data to be presented).

In the phenotypic analysis of healthy tonsil cells, healthy PBMCs, and wAIHA PBMCs, most B cells were CD19+CD20+. In contrast, bone marrow samples contained a distinct CD19+CD20− B-cell population, as well as CD19+CD20+ cells. Consistent with these expression patterns, tafasitamab and rituximab depleted CD19+CD20+ B cells across multiple tissues. Tafasitamab also demonstrated complete depletion of CD19+CD20− bone marrow B-cell populations, while rituximab did not effectively target these cells. In vivo phenotyping showed that peripheral blood B cells comprised ~89% CD19+CD20+ and ~4% CD19+CD20− cells. Consistent with the in vitro phenotypic analysis, in vivo bone marrow B cells were ~36% CD19+CD20+ and ~50% CD19+CD20−, and in vivo spleen B cells were ~73% CD19+CD20+ and ~20% CD19+CD20−. Depletion of CD19+CD20+ B cells in vivo was comparable with tafasitamab and rituximab in all tissues. Tafasitamab treatment also led to depletion of >99% of CD19+CD20− B cells across all tissues; CD19+ B cells were still present following rituximab treatment, especially in spleen and bone marrow tissue.

Conclusions: These findings demonstrate that tafasitamab extends B-cell depletion beyond that achieved with rituximab by effectively targeting CD19⁺CD20⁻ B-cell populations, which may contribute to ongoing autoantibody production and immune activation. This broader CD19-directed depletion may translate into improved therapeutic efficacy in autoimmune diseases.
Daniel Merenich: Incyte Corporation - Stock (publicly traded); Incyte Corporation - Current Employment